AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31232639 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT (sprint interval training) - twice‐weekly all‐out effort cycle sprints consisting of 6 × 10 s sprint with 80 s recovery
Number of subjects: 13
Study 31232639 — intervention group
Group type: COMPARATOR
Intervention: Control group - maintained training
Number of subjects: 13
Study 29310617 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n=36): 3 weekly sessions of 35 min moderate intensity walking/running followed by 25 min resistance training
Number of subjects: 91
Study 29310617 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=34): Standard maternal care
Number of subjects: 91
Study 29310617 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 91
Study 29310617 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 26704739 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose condition
Number of subjects: 73
Study 26704739 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma drug levels
Number of subjects: 73
Study 26704739 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual control sample (n = 128)
Number of subjects: 73
Study 24907875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg, 2 mL)
Number of subjects: 20
Study 24907875 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline, 2 mL)
Number of subjects: 20
Study 22095647 — intervention group
Group type: COMPARATOR
Intervention: Plasma Exchange (PE)
Number of subjects: 19
Study 22095647 — intervention group
Group type: COMPARATOR
Intervention: Immunoadsorption (IA)
Number of subjects: 19
Study 19185287 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg)
Number of subjects: 18
Study 19185287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17365530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic training group
Number of subjects: 22
Study 17365530 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 22
Study 15389189 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 286
Study 15389189 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 286
Study 11555831 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 0
Study 11555831 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics (all groups)
Number of subjects: 0
Study 11555831 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics (progression of nephropathy)
Number of subjects: 0
Study 11555831 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics with advanced nephropathy
Number of subjects: 0
Study 9627171 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 60
Study 9627171 — intervention group
Group type: COMPARATOR
Intervention: Conventional resection
Number of subjects: 60
Study 8179131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.2 mg.kg‐1
Number of subjects: 16
Study 8179131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium 0.2 mg.kg‐1
Number of subjects: 16
Study 2979235 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (70 micrograms)
Number of subjects: 10
Study 2979235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6113682 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg pirenzepine
Number of subjects: 6
Study 6113682 — intervention group
Group type: COMPARATOR
Intervention: 2 ml saline (control)
Number of subjects: 6
Study 31566239 — intervention group
Group type: EXPERIMENTAL
Intervention: Current tobacco users (66.5% of participants)
Number of subjects: 352
Study 31566239 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of tobacco
Number of subjects: 352
Study 31800817 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure intervention with crystal pellets applied to six acupoints (shen men, kidney, stomach, cardia, brainstem, and endocrine) for 12 weeks
Number of subjects: 54
Study 31800817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study 27819460 — intervention group
Group type: EXPERIMENTAL
Intervention: UV4.me (experimental website)
Number of subjects: 965
Study 25934175 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Community Psychiatric Treatment (ICPT)
Number of subjects: 180
Study 25934175 — intervention group
Group type: COMPARATOR
Intervention: Care As Usual (CAU)
Number of subjects: 180
Study 23357152 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM, 500-1000 mg as single shot infusion over 20 min)
Number of subjects: 50
Study 23357152 — intervention group
Group type: COMPARATOR
Intervention: Ferric Gluconate (FG, 62.5 mg once weekly)
Number of subjects: 50
Study 22022915 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer reflection meeting
Number of subjects: 54
Study 22022915 — intervention group
Group type: COMPARATOR
Intervention: Standard feedback strategy without peer reflection
Number of subjects: 54
Study 19542102 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope
Number of subjects: 70
Study 19542102 — intervention group
Group type: COMPARATOR
Intervention: GlideScope
Number of subjects: 70
Study 17521392 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin 40 mg daily
Number of subjects: 44
Study 17521392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 15496219 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg donepezil (single dose)
Number of subjects: 36
Study 15496219 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg donepezil (multiple doses for 23 days)
Number of subjects: 36
Study 15496219 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (5 mg donepezil, single dose)
Number of subjects: 36
Study 15496219 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (5 mg donepezil, multiple doses for 23 days)
Number of subjects: 36
Study 11239307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer aerobic training
Number of subjects: 157
Study 11239307 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training (control)
Number of subjects: 157
Study 9609589 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed estrogen replacement therapy
Number of subjects: 0
Study 9609589 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin hormone replacement therapy
Number of subjects: 0
Study 9609589 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin addition to estrogen therapy
Number of subjects: 0
Study 7816793 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (200 mg t.i.d.)
Number of subjects: 73
Study 7816793 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid (500 mg t.i.d.)
Number of subjects: 73
Study 3150019 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC + FT + PSK
Number of subjects: 579
Study 5337269 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (green and yellow gelatin capsule filled with lactose)
Number of subjects: 48
Study 5337269 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B (red and white capsule containing lactose)
Number of subjects: 48
Study 5337269 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated subjects received a drink of water)
Number of subjects: 48
Study 30566941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 20 mg twice daily
Number of subjects: 75
Study 30566941 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 75
Study 30566941 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study 29091283 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 218
Study 29091283 — intervention group
Group type: COMPARATOR
Intervention: Hepatic resection
Number of subjects: 218
Study 24550168 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 2.5 mg/week
Number of subjects: 395
Study 24550168 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 5 mg/week
Number of subjects: 395
Study 24550168 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 10 mg/week
Number of subjects: 395
Study 24550168 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 20 mg/week
Number of subjects: 395
Study 24550168 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 395
Study 24550168 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 395
Study 24078507 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 117
Study 24078507 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 117
Study 21723176 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational group intervention (four educative workshops led by nurses over one year)
Number of subjects: 2127
Study 21723176 — intervention group
Group type: COMPARATOR
Intervention: Control group (individual care)
Number of subjects: 2127
Study 19128722 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally injected ketorolac
Number of subjects: 140
Study 19128722 — intervention group
Group type: COMPARATOR
Intervention: Intramuscularly injected ketorolac
Number of subjects: 140
Study 19128722 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic alone
Number of subjects: 140
Study 19128722 — intervention group
Group type: COMPARATOR
Intervention: No ketorolac
Number of subjects: 140
Study 17915147 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention in home care unit for up to 15 days after hospital discharge.
Number of subjects: 279
Study 17915147 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 279
Study 15328178 — intervention group
Group type: EXPERIMENTAL
Intervention: Arzoxifene 10 mg daily
Number of subjects: 126
Study 15328178 — intervention group
Group type: EXPERIMENTAL
Intervention: Arzoxifene 20 mg daily
Number of subjects: 126
Study 15328178 — intervention group
Group type: EXPERIMENTAL
Intervention: Arzoxifene 50 mg daily
Number of subjects: 126
Study 15328178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 11276035 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10221828 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate granules in suspension
Number of subjects: 52
Study 10221828 — intervention group
Group type: COMPARATOR
Intervention: antacid
Number of subjects: 52
Study 8174988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid 20% (6 g/h)
Number of subjects: 10
Study 8174988 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg/kg/h)
Number of subjects: 10
Study 8174988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal fat
Number of subjects: 10
Study 8174988 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide
Number of subjects: 10
Study 8174988 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 3591723 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (40% of energy from fat) with P:S ratio of 1.0
Number of subjects: 31
Study 3591723 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (40% of energy from fat) with P:S ratio of 0.3
Number of subjects: 31
Study 3591723 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (20% of energy from fat) with P:S ratio of 1.0
Number of subjects: 31
Study 3591723 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (20% of energy from fat) with P:S ratio of 0.3
Number of subjects: 31
Study 29790457 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan/Fludarabine
Number of subjects: 20
Study 29790457 — intervention group
Group type: COMPARATOR
Intervention: Modified Busulfan/Cyclophosphamide
Number of subjects: 20
Study 28169914 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-paced respiration
Number of subjects: 121
Study 26260776 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with tegafur/gimeracil/oteracil (S‐1 group, n=30)
Number of subjects: 59
Study 26260776 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with tegafur‐uracil (UFT group, n=29)
Number of subjects: 59
Study 26260776 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 group
Number of subjects: 59
Study 26260776 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT group
Number of subjects: 59
Study 23924229 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic feedback strategy using cumulative End‐of‐Life in Dementia (EOLD) scores of a group of patients
Number of subjects: 18
Study 23924229 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient specific feedback strategy using EOLD scores on a patient level
Number of subjects: 18
Study 23924229 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study 21424576 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet (30% energy)
Number of subjects: 23
Study 21424576 — intervention group
Group type: COMPARATOR
Intervention: Usual Protein (UP) diet (15% energy)
Number of subjects: 23
Study 19069030 — intervention group
Group type: EXPERIMENTAL
Intervention: START triage method (colors: green, yellow, red, black)
Number of subjects: 98
Study 16911173 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive group rehabilitation program (psychology-based education, exercise, peer support)
Number of subjects: 55
Study 16911173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 55
Study 12679918 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative radiochemotherapy (40-46 Gy + 5-FU + LV and 5'-DFuR)
Number of subjects: 15
Study 12679918 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy (40-50 Gy) + surgery
Number of subjects: 15
Study 10898185 — intervention group
Group type: EXPERIMENTAL
Intervention: mesna
Number of subjects: 58
Study 10898185 — intervention group
Group type: COMPARATOR
Intervention: saline solution
Number of subjects: 58
Study 8929261 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 11
Study 8929261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1556754 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoint therapy
Number of subjects: 356
Study 1556754 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent therapy
Number of subjects: 356
Study 1556754 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 356
Study 1556754 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual therapy
Number of subjects: 356
Study 1556754 — intervention group
Group type: COMPARATOR
Intervention: Providing efficacy information about alternative formats
Number of subjects: 356
Study 3890528 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of dipyridamole for 2 weeks
Number of subjects: 0
Study 3890528 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 0
Study 29883479 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprexis (internet-based intervention for depression)
Number of subjects: 140
Study 29883479 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 140
Study 27871433 — intervention group
Group type: EXPERIMENTAL
Intervention: HIC hospitals
Number of subjects: 94
Study 27871433 — intervention group
Group type: COMPARATOR
Intervention: MIC hospitals
Number of subjects: 94
Study 25342212 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (20/3.75 mg, loading/maintenance dose)
Number of subjects: 742
Study 25342212 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300/75 mg)
Number of subjects: 742
Study 25342212 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 742
Study 25342212 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 742
Study 23277121 — intervention group
Group type: EXPERIMENTAL
Intervention: Brucella melitensis strain Rev. 1 vaccine (10(6) or 5 × 10(5) live cells)
Number of subjects: 51
Study 23277121 — intervention group
Group type: EXPERIMENTAL
Intervention: Brucella melitensis strain Rev. 1 vaccine (7.5 × 10(6) organisms)
Number of subjects: 51
Study 23277121 — intervention group
Group type: COMPARATOR
Intervention: Non-vaccinated ewes
Number of subjects: 51
Study 20973359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt-chromium femoral component
Number of subjects: 37
Study 20973359 — intervention group
Group type: COMPARATOR
Intervention: Oxidized zirconium femoral component (Control)
Number of subjects: 37
Study 18442345 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg BID
Number of subjects: 2052
Study 18442345 — intervention group
Group type: COMPARATOR
Intervention: Bupropion SR 150 mg BID
Number of subjects: 2052
Study 18442345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2052
Study 15995093 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive of 25 dollars for completing HIV counseling and testing
Number of subjects: 372
Study 15995093 — intervention group
Group type: COMPARATOR
Intervention: No financial incentive (control periods)
Number of subjects: 372
Study 15995093 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall completion of HIV counseling and testing
Number of subjects: 372
Study 12375675 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet therapy and insulin as required
Number of subjects: 0
Study 12375675 — intervention group
Group type: COMPARATOR
Intervention: No specific treatment
Number of subjects: 0
Study 10357958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreservation of all obtained pronucleate embryos (n = 58)
Number of subjects: 125
Study 10357958 — intervention group
Group type: COMPARATOR
Intervention: Fresh embryo transfers (n = 67)
Number of subjects: 125
Study 7579000 — intervention group
Group type: EXPERIMENTAL
Intervention: glipizide (2.5 mg)
Number of subjects: 17
Study 7579000 — intervention group
Group type: EXPERIMENTAL
Intervention: antipyrine (20 mg/kg)
Number of subjects: 17
Study 7579000 — intervention group
Group type: EXPERIMENTAL
Intervention: coumarin (5 mg)
Number of subjects: 17
Study 7579000 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 7579000 — intervention group
Group type: COMPARATOR
Intervention: self‐monitored blood glucose (SMBG) by glucometer
Number of subjects: 17
Study 1657526 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term drug therapy (specific drug not mentioned)
Number of subjects: 0
Study 7169142 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate (ISDN) and Intra-Aortic Balloon Counterpulsation (IABCP)
Number of subjects: 7
Study 7169142 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide Dinitrate (ISDN) alone
Number of subjects: 7
Study 30804314 — intervention group
Group type: EXPERIMENTAL
Intervention: Aegis™ sealant
Number of subjects: 34
Study 30804314 — intervention group
Group type: COMPARATOR
Intervention: Embrace Wetbond™ sealant
Number of subjects: 34
Study 29149745 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol users (B)
Number of subjects: 48
Study 29149745 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural gas users (C)
Number of subjects: 48
Study 29149745 — intervention group
Group type: COMPARATOR
Intervention: Firewood/kerosene users (A)
Number of subjects: 48
Study 27043535 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO+G-CSF
Number of subjects: 9
Study 27043535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 25594755 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy plus bismuth subsalicylate
Number of subjects: 54
Study 25594755 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy plus placebo
Number of subjects: 54
Study 23047592 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐CMF (epirubicin followed by cyclophosphamide, methotrexate and fluorouracil)
Number of subjects: 2391
Study 23047592 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate and fluorouracil)
Number of subjects: 2391
Study 20018946 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 17): face‐to‐face counseling at the first visit, four telephone calls, a video highlighting personal stories, and a cessation guide.
Number of subjects: 35
Study 20018946 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 18): brief face‐to‐face counseling at the first visit and written materials.
Number of subjects: 35
Study 17714570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine with intravenous patient-controlled-analgesia morphine
Number of subjects: 42
Study 17714570 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 42
Study 15902927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cypher sirolimus‐eluting stent
Number of subjects: 0
Study 15902927 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxus paclitaxel‐eluting stent
Number of subjects: 0
Study 15902927 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 0
Study 12296509 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (50 mg/day)
Number of subjects: 29133
Study 12296509 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg/day)
Number of subjects: 29133
Study 12296509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29133
Study 10101629 — intervention group
Group type: EXPERIMENTAL
Intervention: Harpagophytum extract WS 1531 (600 mg)
Number of subjects: 197
Study 10101629 — intervention group
Group type: EXPERIMENTAL
Intervention: Harpagophytum extract WS 1531 (1200 mg)
Number of subjects: 197
Study 10101629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 7791062 — intervention group
Group type: EXPERIMENTAL
Intervention: AMO Vitrax
Number of subjects: 95
Study 7791062 — intervention group
Group type: COMPARATOR
Intervention: Healon
Number of subjects: 95
Study 2170884 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrone sulfate 0.625 mg daily
Number of subjects: 0
Study 2170884 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrone sulfate 1.25 mg daily
Number of subjects: 0
Study 2170884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0